Custopharm, Inc. v. Exela Pharma Sciences, LLC

CourtDistrict Court, S.D. California
DecidedFebruary 4, 2022
Docket3:20-cv-01587
StatusUnknown

This text of Custopharm, Inc. v. Exela Pharma Sciences, LLC (Custopharm, Inc. v. Exela Pharma Sciences, LLC) is published on Counsel Stack Legal Research, covering District Court, S.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Custopharm, Inc. v. Exela Pharma Sciences, LLC, (S.D. Cal. 2022).

Opinion

7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 CUSTOPHARM, INC., a Texas Case No.: 20-cv-01587-AJB-DEB 11 Corporation, 12 ORDER DENYING DEFENDANT’S Plaintiff, MOTION TO DISMISS THE FIRST 13 AMENDED COMPLAINT 14 v. (Doc. No. 17) 15 EXELA PHARMA SCIENCES, LLC, 16 a Delaware Limited Liability Company,

17 Defendant. 18 19 Pending before the Court is Exela Pharma Sciences, LLC’s (“Defendant”) Motion 20 to Dismiss CustoPharm, Inc.’s (“Plaintiff”) First Amended Complaint (“FAC”). (Doc. No. 21 17.) Plaintiff filed an opposition to the motion (Doc. No. 27), and Defendant filed a reply 22 (Doc. No. 28). For the reasons set forth below, the Court DENIES Defendant’s motion. 23 I. BACKGROUND 24 This action stems from an alleged breach of contract. On or about May 19, 2009, 25 Plaintiff entered into a written referral fee agreement (“Referral Agreement”) with 26 Defendant. (Doc. No. 24 ¶ 6.) Under the Referral Agreement, Plaintiff agreed to refer 27 business to Defendant “for the production of pre-launch clinical trial materials and 28 production of development and commercial drug products[.]” (Id.) In turn, Defendant 1 promised to (1) “keep any such information disclosed by [Plaintiff] confidential and not 2 disclose such information to any third party, or use such information for their own benefit 3 to start a new project” and (2) “pay [Plaintiff a] five percent (5%) commission on all 4 payments received from any referral that resulted in a drug product being manufactured by 5 [Defendant].” (Id. ¶ 8.) The commission included “any payments received from the 6 referral, including payments received from R & D work, pre-launch development activities, 7 commercial drug produce [sic] manufacturing and royalties from referred business.” (Id. 8 ¶ 9.) Commission payments were due within thirty days of Defendant receiving payments 9 from the referred business, with a one and a half percent (1.5%) late fee. (Id.) 10 At the time of the Referral Agreement, “there were six (6) companies that [Plaintiff] 11 identified and [Defendant] acknowledged had been referred pursuant to the terms of the 12 Referral Agreement.” (Id. ¶ 10.) Since the parties executed the Referral Agreement, the 13 number of referred companies “grew to at least eleven (11) companies.” (Id.) 14 “The Referral Agreement allowed either party to terminate the Referral Agreement 15 ‘with six months written notice with all existing business surviving termination[.]’” (Id. 16 ¶ 11 (quoting the Referral Agreement).) On or about April 19, 2012, Defendant provided 17 written notice to terminate the Referral Agreement and proposed new terms and 18 obligations, including revising the survivability provision. (Id. ¶ 12.) Plaintiff accepted 19 only the termination notice and never agreed to the proposed new terms. (Id. ¶ 13.) 20 Defendant’s termination notice became effective on October 19, 2012. (Id.) 21 After termination, Plaintiff claims Defendant made two referral payments under the 22 Referral Agreement in 2013 and 2014. (Id. ¶ 15.) From 2015 to 2020, Plaintiff inquired 23 with Defendant if Defendant “was conducting business with any of the eleven (11) 24 companies listed in the Referral Agreement and whether any commissions were owed to 25 [Plaintiff].” (Id.) Plaintiff claims Defendant “never identified any such business and never 26 disclosed that, in fact, it had received revenues” from some of the eleven companies. (Id.) 27 Plaintiff further alleges there was no way to verify Defendant’s information and relied on 28 Defendant to provide truthful and accurate information. (Id. ¶ 16.) 1 Plaintiff alleges that it first learned that Defendant was conducting business with the 2 referred companies and owed commissions to Plaintiff in June 2020, through a third-party. 3 (Id. ¶ 17.)1 Plaintiff thereafter contacted Defendant, and Defendant allegedly provided 4 Plaintiff a spreadsheet indicating “over $1.1 million was earned and owed in commissions 5 under the Referral Agreement since 2015.” (Id. ¶ 18.) Plaintiff demanded payment but 6 Defendant allegedly “refused claiming some newly created offset as an excuse not to pay.” 7 (Id. ¶ 19.) The FAC asserts claims for (1) breach of contract, (2) accounting, and (3) 8 declaratory relief. The instant motion to dismiss the FAC pursuant to Federal Rule of Civil 9 Procedure (“Rule”) 12(b)(6) follows. 10 II. LEGAL STANDARD 11 A Rule 12(b)(6) motion to dismiss tests the legal sufficiency of the complaint. 12 Navarro v. Block, 250 F.3d 729, 732 (9th Cir. 2001). “To survive a motion to dismiss, a 13 complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief 14 that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citation omitted). 15 Facial plausibility is satisfied “when the plaintiff pleads factual content that allows the 16 court to draw the reasonable inference that the defendant is liable for the misconduct 17 alleged.” Id. The plausibility standard is not a probability requirement but rather “asks for 18 more than a sheer possibility that a defendant has acted unlawfully.” Id. 19 To determine the sufficiency of the complaint, the court must assume the truth of all 20 factual allegations therein and construe them in the light most favorable to the plaintiff. 21 Cahill v. Liberty Mut. Ins. Co., 80 F.3d 336, 337–38 (9th Cir. 1996). This tenet, however, 22 does not apply to legal conclusions. Iqbal, 556 U.S. at 678. “Threadbare recitals of the 23 elements of a cause of action, supported by mere conclusory statements, do not suffice.” 24 Id.; Bell Atlantic Corp. v. Twombly, 550 U.S. 544, 555 (2007). “[W]here the well-pleaded 25 facts do not permit the court to infer more than the mere possibility of misconduct,” the 26 complaint is subject to dismissal. Iqbal, 556 U.S. at 679. 27

28 1 Defendant filed a motion seal the information related to this discovery as confidential and sensitive to 1 III. DISCUSSION 2 The Court previously granted Defendant’s first motion to dismiss, finding that 3 Plaintiff’s original complaint did not plead enough facts to toll the application of the statute 4 of limitations in this case. (Doc. No. 13.) With its second motion to dismiss, Defendant 5 contends that Plaintiff’s FAC still fails to show that the statute of limitations does not bar 6 its breach of contract claim. (Doc. No. 17 at 5.)2 Defendant further argues Plaintiff’s 7 accounting and declaratory relief claims fail because both are dependent on the breach of 8 contract claim that is time-barred and inadequately pled. (Id. at 14.) Plaintiff maintains that 9 its claims are timely, and that Defendant breached the Referral Agreement when it failed 10 to pay the commissions it owed Plaintiff. (Doc. No. 27 at 9.) The Court discusses the 11 viability of Plaintiff’s claims in turn. 12 A. Breach of Contract 13 Defendant asserts that the statute of limitations bars Plaintiff’s breach of contract 14 claim. Neither party disputes that California law applies in this case. (Doc. Nos. 17 at 9; 15 27 at 9.) “[T]he elements of a cause of action for breach of contract are (1) the existence of 16 the contract, (2) plaintiff’s performance or excuse for nonperformance, (3) defendant’s 17 breach, and (4) the resulting damages to the plaintiff.” Oasis West Realty, LLC v. Goldman, 18 51 Cal.4th 811, 821 (2011). California’s statute of limitations for a written contract is four 19 years. Cal. Code Civ. Proc. § 337.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Reno v. Catholic Social Services, Inc.
509 U.S. 43 (Supreme Court, 1993)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
United States v. State Of Washington
759 F.2d 1353 (Ninth Circuit, 1985)
Aryeh v. Canon Business Solutions, Inc.
292 P.3d 871 (California Supreme Court, 2013)
Oasis West Realty v. Goldman
250 P.3d 1115 (California Supreme Court, 2011)
Niles v. Louis H. Rapoport & Sons, Inc.
128 P.2d 50 (California Court of Appeal, 1942)
Von Saher v. Norton Simon Museum of Art at Pasadena
592 F.3d 954 (Ninth Circuit, 2010)
April Enterprises, Inc. v. KTTV
147 Cal. App. 3d 805 (California Court of Appeal, 1983)
Teselle v. McLoughlin
173 Cal. App. 4th 156 (California Court of Appeal, 2009)
Gryczman v. 4550 Pico Partners, Ltd.
131 Cal. Rptr. 2d 680 (California Court of Appeal, 2003)
Tsemetzin v. Coast Federal Savings & Loan Ass'n
57 Cal. App. 4th 1334 (California Court of Appeal, 1997)
Perez-Encinas v. Amerus Life Insurance
468 F. Supp. 2d 1127 (N.D. California, 2006)
Fox v. Ethicon Endo-Surgery, Inc.
110 P.3d 914 (California Supreme Court, 2005)
Snyder v. California Insurance Guarantee Assn.
229 Cal. App. 4th 1196 (California Court of Appeal, 2014)
Navarro v. Block
250 F.3d 729 (Ninth Circuit, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
Custopharm, Inc. v. Exela Pharma Sciences, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/custopharm-inc-v-exela-pharma-sciences-llc-casd-2022.